How Does Inclisiran Compare to Other Lipid-lowering Agents?
Inclisiran differs from traditional statins and PCSK9 inhibitors like monoclonal antibodies (e.g., alirocumab, evolocumab) in its mechanism of action and dosing frequency. Statins inhibit cholesterol synthesis, while monoclonal antibodies directly bind to PCSK9. Inclisiran, on the other hand, reduces PCSK9 production at the mRNA level.
In terms of toxicity, inclisiran has shown a favorable profile compared to some statins, which can cause muscle-related side effects and liver enzyme elevations. The biannual dosing of inclisiran also reduces the risk of non-compliance compared to more frequently administered therapies.
